Angiotensin III (human, mouse): Molecular Insights for Cardiovascular and Viral Pathogenesis Research

Introduction

Angiotensin III (human, mouse), a biologically active hexapeptide with the sequence Arg-Val-Tyr-Ile-His-Pro-Phe, has long been appreciated as a pivotal component of the renin-angiotensin-aldosterone system (RAAS). While its pressor and aldosterone-stimulating effects are well established, recent advances highlight its nuanced receptor selectivity, signaling diversity, and unexpected roles in viral pathogenesis. Here, we provide a comprehensive, molecularly focused review of Angiotensin III's mechanisms, pharmacological properties, and emerging research applications—uniquely integrating its dual relevance in cardiovascular and infectious disease models.

Biochemical Profile and Solubility of Angiotensin III (human, mouse)

Angiotensin III (CAS: 13602-53-4) is produced by N-terminal cleavage of angiotensin II via angiotensinase activity in erythrocytes and various tissues. The peptide, with a molecular weight of 931.09 Da (chemical formula C₄₆H₆₆N₁₂O₉), is remarkable for its high solubility: ≥23.2 mg/mL in water, ≥43.8 mg/mL in ethanol, and ≥93.1 mg/mL in DMSO.

This physicochemical profile, combined with robust stability when stored desiccated at -20°C, makes Angiotensin III (human, mouse) (SKU: A1043) from APExBIO a reliable tool for rigorous cardiovascular and neuroendocrine signaling studies. Long-term storage in solution is not recommended to preserve activity.

The Renin-Angiotensin-Aldosterone System (RAAS) and Angiotensin III

Contextualizing Angiotensin III within RAAS

The RAAS orchestrates systemic blood pressure, fluid balance, and electrolyte homeostasis. Within this cascade, angiotensinogen is first cleaved by renin to form angiotensin I (1–10). Angiotensin-converting enzyme (ACE) then generates angiotensin II (1–8), the classical effector of vasoconstriction and aldosterone release. Angiotensin II is further processed to angiotensin III (2–8), which retains full aldosterone-stimulating capacity and mediates up to 40% of the pressor activity attributed to angiotensin II. The transition from angiotensin II to angiotensin III is not merely degradative but generates a distinct bioactive entity with unique receptor affinities and downstream effects.

Mechanisms of Action: AT1 and AT2 Receptor Signaling

Receptor Binding and Functional Specificity

Angiotensin III functions as a potent AT1 and AT2 receptor ligand. While it activates both receptor subtypes, it exhibits a notable relative specificity for the AT2 receptor. The AT1 receptor predominantly mediates vasoconstriction and fluid retention, whereas AT2 receptor signaling is linked with vasodilation, anti-fibrotic, and anti-inflammatory responses. This receptor selectivity underpins the duality of angiotensin III's physiological actions:

• Pressor Activity Mediator: Angiotensin III contributes significantly to blood pressure regulation, accounting for a substantial proportion of the vasopressor effects in the RAAS.
• Aldosterone Secretion Inducer: It robustly stimulates aldosterone release from the adrenal cortex, influencing sodium retention and potassium excretion.
• Renin Suppression: Exogenous administration of angiotensin III suppresses renin release, closing the regulatory feedback loop.

In rodent brain models, angiotensin III elicits both pressor and dipsogenic (thirst-stimulating) responses—making it invaluable for dissecting neuroendocrine signaling peptide mechanisms within the central nervous system.

Angiotensin III in Viral Pathogenesis: Beyond Cardiovascular Research

Enhancement of SARS-CoV-2 Spike Protein Binding

Recent research has revealed a striking role for angiotensin peptides—including Angiotensin III—in modulating viral-host interactions. A seminal study by Oliveira et al. (2025, Int. J. Mol. Sci.) demonstrated that naturally occurring angiotensin peptides enhance the binding of the SARS-CoV-2 spike protein to its host cell receptors, such as AXL, especially in cells with low ACE2 expression. Importantly, N-terminally truncated peptides like Angiotensin III (2–8) exhibited an even greater capacity to potentiate spike–AXL interactions compared to the classical octapeptide angiotensin II.

This unexpected finding suggests that Angiotensin III may influence COVID-19 pathogenesis by increasing susceptibility to infection through spike protein facilitation. These mechanistic insights set the stage for leveraging Angiotensin III as a probe in viral infection models, complementing its established utility in hypertension research and cardiovascular disease models.

Comparative Analysis: Angiotensin III Versus Alternative RAAS Peptides

Previous articles, such as "Angiotensin III (human, mouse): Next-Generation Peptide for RAAS Research", have explored the advanced roles and receptor selectivity of Angiotensin III in cardiovascular and neuroendocrine research. While those works focus on receptor-mediated effects and translational applications, the present article delves deeper into the molecular mechanisms linking Angiotensin III to both cardiovascular regulation and viral susceptibility, as recently elucidated in COVID-19 studies.

Unlike angiotensin II, which primarily targets the AT1 receptor, Angiotensin III's relative AT2 receptor specificity opens new experimental avenues—particularly for dissecting anti-inflammatory and anti-fibrotic pathways. Its superior solubility and stability (as provided by APExBIO's formulation) further distinguish it from less robust RAAS peptides in advanced experimental workflows.

Advanced Applications in Cardiovascular, Neuroendocrine, and Viral Research

Modeling Human Disease: Hypertension and Beyond

Angiotensin III's ability to reliably induce both pressor and dipsogenic responses makes it a gold-standard cardiovascular research peptide for modeling hypertension, heart failure, and neuroendocrine disorders. For example, in rodent studies, central or peripheral administration of Angiotensin III can dissect the relative contributions of AT1 versus AT2 signaling in blood pressure regulation and aldosterone secretion. Its unique functional attributes also enable mechanistic studies on the feedback suppression of renin, clarifying RAAS homeostatic control.

Translational Relevance in Viral Pathogenesis

Building on the findings from Oliveira et al. (2025), Angiotensin III now serves as a critical probe in viral pathogenesis studies, particularly for SARS-CoV-2. By enhancing spike–AXL binding, it provides a platform to:

• Investigate the intersection of cardiovascular and infectious disease risk.
• Screen for therapeutic inhibitors that block spike–receptor interactions potentiated by angiotensin peptides.
• Model the impact of RAAS dysregulation on viral entry and propagation in humanized cell and animal models.

This dual applicability bridges a gap not previously addressed in articles such as "Angiotensin III (human, mouse): Optimizing RAAS Research", which focused primarily on assay optimization and reliability rather than on the mechanistic interplay between RAAS peptides and viral pathogenesis. Our present analysis uniquely synthesizes cardiovascular and virological perspectives, empowering researchers to leverage Angiotensin III in both domains.

Enhancing Experimental Design and Troubleshooting

With its robust solubility, stability, and validated activity, Angiotensin III is particularly well-suited for complex experimental designs—ranging from receptor pharmacology to in vivo disease modeling. Its reliable performance, as supplied by APExBIO, addresses experimental reproducibility issues often encountered with less-characterized RAAS peptides.

While other articles, like "Angiotensin III: Transforming RAAS Experimental Workflows", have emphasized workflow optimization and translational relevance, the present work prioritizes the peptide's molecular characteristics and its expanding role at the interface of cardiovascular and infectious disease research.

Conclusion and Future Outlook

Angiotensin III (human, mouse) is far more than a classic RAAS effector; it is a sophisticated molecular tool that bridges cardiovascular, neuroendocrine, and viral pathogenesis research. Its distinctive Arg-Val-Tyr-Ile-His-Pro-Phe sequence, robust receptor selectivity, and emerging role in enhancing viral spike protein binding position it as a next-generation reagent for experimental and translational science. As research on the RAAS–virus interface accelerates, Angiotensin III is poised to illuminate new therapeutic strategies and mechanistic insights into disease processes where cardiovascular and infectious pathways converge.

For researchers seeking a high-quality, well-characterized renin-angiotensin-aldosterone system peptide, Angiotensin III (human, mouse) from APExBIO offers unmatched performance and reliability. As new frontiers in hypertension, cardiovascular disease models, and viral pathogenesis emerge, this peptide will remain an essential asset for innovative experimental design and discovery.